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Abstract
Characteristics of inhibitors identified by prospective screening may differ from those detected 
clinically. In a prospective study at 17 hemophilia centers with central inhibitor measurement by 
Nijmegen-Bethesda assay, 23 (2.8%) of 824 hemophilia A patients had new inhibitors detected: 
nine high-titer inhibitors (HTI: 7 ≥5.0 NBU plus 2 of 2.6 and 3.4 NBU at immune tolerance 
induction initiation) and 14 low-titer inhibitors (LTI: 0.5–1.9 NBU). HTI occurred at an earlier age 
(median 2 years, range 1–18, vs. median 11 years, range 2–61, P = 0.016). Both HTI (22%) and 
LTI (43%) occurred in non-severe patients. All HTI, but only 64% of LTI, were found to be 
FVIII-specific by chromogenic Bethesda assay or fluorescence immunoassay (FLI), indicating a 
high rate of false-positive LTI. Repeat specimens confirmed all HTI, 7/9 LTI, and 7/7 FVIII-
specific LTI. FLI results were similar between HTI and FVIII-specific LTI; all included IgG1 and 
IgG4 subclasses. A comparable prospective study conducted from 1975 to 1979 at 13 U.S. centers 
found 31 (2.4%) new inhibitors among 1,306 patients. In both studies, one-third of inhibitors 
occurred in non-severe patients and one-quarter after 150 exposure days (ED). Significant 
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differences were seen in the age at which inhibitors occurred (median 16 years in the older study 
vs. 5 years currently, P = 0.024) and in ED before inhibitor development, 10% in the older study 
and 43% currently study occurring within 20 ED, suggesting a temporal change in inhibitor 
development. Prospective screening detects inhibitors in patients of all severities, ages, and ED. 
Some LTI, however, are false positives.
Introduction
The development of neutralizing antibodies, referred to as inhibitors, is a significant 
treatment-associated complication experienced by a subset of hemophilia A (HA) patients 
following factor VIII (FVIII) infusion therapy. Inhibitors complicate patient management by 
limiting the effectiveness of FVIII infusions in stopping and/or preventing bleeding 
episodes. Knowledge of the incidence and prevalence of inhibitors is important to assess the 
burden of inhibitors on the community and to identify trends in inhibitor occurrence [1]. 
Few large studies have involved prospective monitoring for inhibitors among previously 
treated patients of all severities in the U.S. [2]. The Hemophilia Inhibitor Research Study 
(HIRS) conducted by the Centers for Disease Control and Prevention (CDC) at 17 U.S. 
hemophilia treatment centers (HTCs) included prospective monitoring for inhibitors through 
testing in a central laboratory and collection of individual treatment records [3]. The 
modified Nijmegen-Bethesda assay (NBA) used in the study allowed measurement of FVIII 
inhibitors in the presence of infused factor VIII [4]. Comparison of the NBA results with 
results of a chromogenic Bethesda assay (CBA) and a fluorescence immunoassay (FLI) for 
anti-FVIII antibodies showed that 26% of NBA-positive specimens with Nijmegen-Bethesda 
units <2.0 failed to react with FVIII in both the CBA and FLI, indicating a high rate of false-
positive results among low-titer inhibitors [5]. This report further describes the 
characteristics of the patients with inhibitors detected by this prospective screening program, 
compares these results to an earlier U.S. prospective study, and discusses the implications of 
the findings for surveillance and clinical management.
Materials and Methods
Subjects
People with HA having FVIII activity <50 International Units per deciliter were enrolled 
from 2006 to 2012 at 17 U.S. Hemophilia Treatment Centers in a study of prospective 
monitoring for inhibitors, which is described in detail elsewhere [3]. Demographic data and 
information on number of exposure days (ED) before enrollment and previous inhibitor 
history were collected from the enrolling site using standardized data collection tools. 
Treatment product exposure records were collected prospectively from the time of 
enrollment. Inhibitor measurements were performed centrally at CDC at study entry, 
annually, before any planned product switch, or for clinical indication of an inhibitor. After 
detection of an elevated inhibitor titer in a previously negative patient, additional data were 
collected on outcomes. The protocol was approved by the investigational review boards of 
CDC and each participating site, and all participants or parents/guardians of minor children 
gave informed consent. The population studied included 824 patients with HA and no 
previous history of an inhibitor according to the enrolling sites. Severity was reported by the 
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sites as 498 (60%) severe, 135 (16%) moderate, and 191 (23%) mild. For this report, the 
clinical characteristics of the 23 HA patients with new inhibitors detected during the study 
are described.
Laboratory methods
Factor VIII inhibitors were measured using a modified Nijmegen-Bethesda assay (NBA), in 
which patient plasma was heated to 56°C for 30 minutes and centrifuged before testing, as 
previously described [4], and expressed in Nijmegen-Bethesda units (NBU). For selected 
specimens, a CBA, expressed in chromogenic Bethesda units (CBU) and a FLI for FVIII 
antibodies using combined immunoglobulin G (IgG) and immunoglobulin M (IgM) were 
also performed as previously described [5]. Immunoglobulin subclasses were determined by 
FLI [6]. Factor VIII gene sequencing, FVIII inversion testing, and multiple ligand probe 
amplification were carried out by published methods [7]. Dilute Russell’s viper venom time 
(DRVVT) was measured using DVVtest and DVVconfirm reagents (American Diagnostica, 
Stamford, CT). Heparin was quantitated using an anti-factor Xa assay (Liquid Anti-Xa 
Assay, Diagnostica Stago, Parsippany, NJ).
Statistical methods
Comparisons using Fisher’s exact or Chi-square tests were calculated as appropriate using 
GraphPad Prism, Version 5 (GraphPad Software Inc., San Diego, CA). Results were 
considered significant at the 0.05 level.
Results
A prospective monitoring study of 824 HA patients with no previous history of an inhibitor 
identified an inhibitor in 23 patients (2.8%). Characteristics of these 23 patients are shown in 
Table I. Nine inhibitors (two high titer) were detected at enrollment in patients reported by 
the enrolling sites to be negative; 14 developed in patients in whom a negative result was 
documented in the central laboratory at enrollment. Distributions of severity, age, ethnicity, 
exposure days to factor products (ED), and mutation type were similar for the two groups of 
patients, and the groups were combined for further analysis.
Peak inhibitor titers before initiation of immune tolerance induction therapy (ITI) were used 
for classification. Seven patients (30%) had inhibitors ≥5.0 NBU. Two (9%) had inhibitors 
of 2.6 and 3.9 NBU and were placed on ITI immediately following their inhibitor detection. 
Fourteen (61%) had inhibitors of 0.5–1.9 NBU. For purposes of analysis, the 2.6 and 3.9 
NBU patients were included in the high-titer group. Table II shows characteristics of the 
patients with high-titer inhibitors (HTI) and low-titer inhibitors (LTI), as well as those LTI 
which were identified as being FVIII-specific and non-specific by reaction in the CBA 
and/or FLI.
High-titer inhibitors
HTI were identified in nine patients, including seven with inhibitors detected during study 
monitoring and two detected at enrollment. Eight patients were between 1 and 5 years old at 
the time of initial inhibitor detection; one was 18 years old. Among the younger patients, 
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four had fewer than 20 ED, three had 21–50 ED, and one had 52 ED; the 18-year-old was 
reported to have between 21 and 100 ED. Four inhibitors were first detected locally, and five 
were detected through study screening at annual visits or before a planned product switch. 
Six were positive on multiple specimens with peak titers ranging from 6.5 to 688.2 NBU. 
The two patients placed on ITI immediately (Patients 8 and 9) were not retested in the 
central laboratory.
Of the two patients with HTI detected at enrollment, one was a 3-year-old with fewer than 
20 EDs who had an inhibitor titer of 54.4 NBU (Patient 3). The results of previous local 
inhibitor testing were not reported by the site. The other patient was an 18-year-old with 
moderate hemophilia whose initial study result was 10.2 NBU (Patient 2). A test performed 
three years before enrollment by the patient’s HTC was reported as negative. Six months 
after the positive study test result reported to the HTC, a local test was said to be negative. 
The patient presented for an emergency appendectomy one year later and was treated with 
several FVIII products, with hemostasis achieved only with recombinant factor VIIa. The 
peak inhibitor titer detected by the CDC laboratory post-surgery was 55.6 NBU. These two 
patients and Patient 4 were not noted to have clinical indication of an inhibitor at the time 
that their positive study specimens were submitted.
Low-titer inhibitors
LTI were detected in 14 patients ranging from 2 to 61 years of age. Seven were detected 
during study monitoring and seven at enrollment. Of the nine LTI patients with repeat 
specimens available, seven (78%) were consistently positive, while two were negative on 
repeat specimens. One LTI patient became negative within three months, but his inhibitor 
reappeared two years later (Patient 15). One LTI was detected locally (Patient 12), and two 
other specimens were submitted due to poor response to treatment (Patients 10 and 11). 
Eleven were not noted to have clinical indication of an inhibitor. Three patients with LTI 
were over age 40. Patient 11 had mild disease and fewer than 20 ED. His inhibitor appeared 
at age 46, three weeks after he underwent surgery for hernia repair and liver biopsy. His 
mutation, Ser535Gly, is one of the missense mutations previously seen with inhibitors [8]. 
Patients 13 and 16, who were severe and moderate, respectively, had >150 ED. Their 
inhibitors were detected at enrollment, and the events surrounding their occurrence are not 
known. Patient 13 was 61 years old and reported to have history of intracranial hemorrhage 
and drug allergies; he had no recent procedures. Additional data on Patient 16, age 41, were 
not available.
Comparison of HTI and LTI
Subjects with HTI were younger at inhibitor detection than those with LTI (median age 2 
years vs. 11 years, P = 0.016). All HTI were seen in patients age 18 or younger, while LTI 
occurred in patients with a wide age distribution, including three patients over 40 years of 
age (Fig. 1A). Despite the difference in the age distributions, the proportions of HTI and LTI 
patients with fewer than 20 EDs were similar, 44% and 43%, respectively, due to the 
presence of more mild and moderate patients in the LTI group. All HTI developed within 
the first 150 ED, while 43% of LTI developed after 150 ED (Fig. 1B). Race and mutation 
type frequencies were similar between HTI and LTI groups (Table II). All HTI required 
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change in treatment to a bypassing agent, ITI, or both; whereas, only 43% of those with LTI 
underwent a treatment change (P = 0.029).
FVIII specificity
CBA and anti-FVIII FLI were performed on all samples that tested positive by the NBA to 
rule out non-FVIII-specific inhibition of the clot-based assay. All HTI tested gave positive 
reactions in the CBA and FLI (Table III). For eight of the 14 LTI, FVIII specificity was 
indicated by a positive reaction in the CBA. Seven of the eight were also positive by FLI; 
one was not tested. Patient 17 with 0.7 NBU was CBA-negative at 0.3 CBU and negative by 
FLI using combined IgG/IgM reagents at 0.36 (negative <0.47). He remained NBA-positive 
at 0.5 NBU and CBA-negative 16 months later, when testing for immunoglobulin subclass 
determination [6] revealed positivity for IgG1 and IgG4. Among the 5 LTI not shown to be 
FVIII-specific were those from Patients 19 and 20, who at ages 18 and 29 had titers of 1.3 
and 0.9 NBU despite having received no treatment other than desmopressin, clearly 
illustrating false positive test results; Patient 22, whose inhibitor titer decreased from 0.7 
NBU to 0.3 NBU within 1 month, representing either a false positive or a transient inhibitor; 
and Patients 21 and 23, whose inhibitors of 0.8 and 0.6 NBU detected late in the study were 
not repeated, but as both were negative in the CBA, which is more sensitive than the NBA 
[5], are also likely to be false positives. Four of the five non-FVIII-specific specimens had 
negative DRVVT; Patient 23 was not tested. None of the specimens had heparin 
contamination. Overall, 36% of LTI, with titers of 0.6–1.3 NBU, failed to react in the CBA 
or FLI. FVIII-specific LTI had similar titers of 0.5–1.8 NBU but remained positive over 
time and more often resulted in treatment change than LTI that were not FVIII-specific 
(Table II).
Levels of antibodies binding to FVIII in the FLI (Table III) were similar among patients 
with HTI (median 2.89, range 0.54–7.89) and FVIII-specific LTI (median 2.71, range 0.50–
6.17). Immunoglobulin subclass types also were similar between HTI and LTI, with all 
FVIII-specific inhibitors tested having IgG1 and IgG4.
Study comparison
Table IV compares data from the current study with the only similar prospective study of 
inhibitors in the U.S., which was conducted by the National Heart, Lung, and Blood Institute 
(NHLBI) between 1975 and 1979 [2]. Among 1,306 enrolled HA patients, 31 new inhibitors 
(2.4%) were detected. Of patients developing inhibitors, 32% and 35% were non-severe in 
the NHLBI study and the current study, respectively. Clinical indications prompted testing 
for an inhibitor before study screening in 35% and 39% of patients who developed new 
inhibitors in the NHLBI and the current study, respectively, and repeat specimens were 
positive in 77% of the NHLBI patients and 88% of the patients in the current study. The age 
ranges at time of inhibitor development were similar, but median age was significantly 
higher in the earlier study (16 years vs. 5 years, P = 0.024) (Fig. 2A). Later occurrence of 
inhibitors is also suggested by a significant difference in the distribution of EDs (Chi-square 
= 31.0, P = 0.032), with 10% of inhibitors in the early study and 43% in the current study 
developing before 20 ED (Fig. 2B). Age distributions for the enrolled subjects in the two 
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studies were not significantly different (data not shown); distribution of EDs for the entire 
NHBLI population was not provided [9]
Discussion
The findings from prospective studies have important implications for both clinical 
management and population surveillance. For both purposes, it is crucial that the appropriate 
population is monitored and that tests are used that minimize the number of false results, 
both false positive and false negative. In this prospective study on inhibitor development in 
HA patients, HTI occurred in non-severe as well as severe patients. Although almost one-
half of all inhibitors occurred within the first 20 EDs in both LTI and HTI groups, there was 
a second peak of inhibitor development in the LTI group that occurred after 150 EDs. This 
difference accounted for the significant median age difference between HTI and LTI groups. 
The LTI group included three patients over age 40, although one was mild with fewer than 
20 ED at the time of inhibitor development. These findings are similar to the report from the 
United Kingdom of a second peak of inhibitors later in life [10].
At the time of initial detection, it is not possible to determine whether a LTI will progress to 
a high-responding inhibitor, remain low-responding, or be transient [11]. In the current 
study, 39% of new inhibitors detected had not yet come to clinical attention. Early 
recognition of inhibitors may improve outcomes of ITI, which is reported to be more 
effective at lower titers [12]. Although the modified NBA used in this study facilitates 
patient screening, because it allows for testing patients with exogenous FVIII present [4], 
traditional inhibitor assays may miss LTIs if a wash-out period is not employed, because the 
presence of residual infused FVIII can act as a reservoir for anti-FVIII antibodies, thereby 
decreasing the observed inhibitor titer and potentially producing a false-negative test result. 
This study also demonstrates that false-positive results can occur but illustrates that they can 
be distinguished from true positives by performing follow-up tests and utilizing alternative 
testing methods to confirm FVIII specificity.
The validity of a single LTI result is often questioned due to the known high rate of false-
positive tests, which has been documented by proficiency testing programs in North 
America and attributed to differences in the test methods used [13]. Indeed, 70% of North 
American coagulation laboratories report using a hybrid of Bethesda and Nijmegen methods 
and not strictly following either [14]. Such differences make it difficult to compare results 
among laboratories and to collect national data on inhibitor occurrence. Using carefully 
standardized methods in a single laboratory, we have shown it is possible to achieve a high 
rate of precision for known positive and negative specimens [4]. We also found, however, 
that one-quarter of all inhibitors <2.0 NBU in the NBA failed to react with FVIII in more 
sensitive and specific assays [5]. These discrepancies may be due to assay variability, lupus 
anticoagulants, or non-specific inhibition of clot-based assays. Use of alternative assays, 
particularly the CBA, which can be performed in many clinical laboratories with automated 
analyzers, allows rapid identification of true positive inhibitors that our current data suggest 
may be more likely to persist and require treatment change. These data, and the fact that 
CBA and NBA results correlate well for inhibitors greater than 2.0 NBU [5], suggest that the 
adoption of the CBA for all inhibitor testing might be advantageous.
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The clinical significance of persistent LTIs is not well documented; however, our limited 
data show that almost one-half of those with FVIII-specific LTI were placed on by-passing 
agents. It is also of interest that levels of antibodies directed against FVIII, as measured by 
FLI, were often as high in those with LTI as in those with HTI, suggesting that in some 
patients the NBA titer may not accurately reflect the antibody load. In addition, FVIII-
specific LTI contained both IgG1 and IgG4 subclasses, a pattern similar to that seen in HTI 
[6,15]. Clinically, response to therapy is the most useful determinant of the significance of a 
LTI [11], but data on clinical response were not collected in this study. Further studies on 
the natural history and clinical significance of LTI are warranted.
A national cooperative study conducted by the NHLBI from 1975 to 1979 in 1,306 HA 
patients at 13 hemophilia treatment centers [2] is the only prospective U.S. study 
comparable in size to HIRS involving a patient population including all hemophilia 
severities. In spite of the changes seen in treatment over the past 35 years, characteristics of 
patients identified with inhibitors in the two studies were similar. Both studies found close to 
one-third of new inhibitors occurring in non-severe patients and more than one-quarter in 
those with >150 ED. Only 35% and 39% of inhibitors were detected due to clinical 
suspicion of an inhibitor and the rest by study screening. The proportion of detected 
inhibitors negative on repeat specimens was 24% in the NHLBI study, but only 12% in 
HIRS, perhaps reflecting improved specificity of the Nijmegen method over the Bethesda 
assay for inhibitor detection, although the difference was not statistically significant. There 
were two striking differences between the groups of patients with new inhibitors identified. 
In HIRS, the inhibitors occurred at a significantly earlier age with a median age of 5 years 
compared to 16 years in the NHLBI study. There was also a shift in the distribution of EDs: 
43% of HIRS inhibitors occurred before 20 EDs, compared to only 10% of those in the 
NHLBI study, in which 45% of new inhibitors occurred between 21 and 100 ED. During the 
NHLBI study, only plasma-derived factor VIII concentrates were available, and their 
introduction was relatively recent after prior dependence on cryoprecipitate and plasma 
treatment. This temporal shift in inhibitor occurrence could reflect the change from plasma-
derived to recombinant factor. The appearance of inhibitors in younger patients may explain 
the perception that more inhibitors appeared with introduction of recombinant products, 
although a difference often could not be documented in studies conducted at the time [16]. 
Other changes in treatment practices, such as introduction of factor concentrates earlier in 
life and prophylaxis, may also have contributed. Neither the NHLBI study nor the current 
study was restricted to previously untreated patients and thus cannot address the important 
question of immunogenicity in that population. These two prospective studies, with 
strikingly similar results although decades apart, show that the population at risk for 
inhibitors includes patients of all severities, ages, and EDs and that more than one-third of 
HTIs had not been recognized clinically at the time of laboratory detection.
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Figure 1. 
Comparison of high titer and low titer inhibitors for age at inhibitor detection (A) and 
exposure days before inhibitor detection (B). Bar represents the median.
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Figure 2. 
Comparison of 1975–1979 study [2] and current study for age at inhibitor detection (A) and 
exposure days before inhibitor detection (B). Bar represents the median.
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TABLE II
Clinical Characteristics of Patients With New Inhibitors Detected, Including High Titer, Low Titer, and Factor 
VIII (FVIII)-Specific Low Titer (Positive in Chromogenic Bethesda Assay and/or Fluorescence 
Immunoassay), n (%)
High All Low FVIII-Specific Low FVIII Non-Specific Low
Number of patients 9 14 9 5
Age
 Median 2 11a 5 15a
 Range 1–18 2–61 2–61 6–29
Severity
 Severe 7 (78) 8 (57) 6 (67) 2 (40)
 Moderate 2 (22) 2 (14) 1 (12) 1 (20)
 Mild 0 4 (29) 2 (25) 2 (40)
Exposure days
 0–20 4 (44) 6 (43) 3 (38) 3 (60)
 21–100 4 (44) 1 (7) 1 (12) 0
 101–150 1 (11) 1 (7) 1 (12) 0
 >150 0 6 (43) 4 (44) 2 (40)
Race
 White 5 (56) 11 (79) 6 (67) 5 (100)
 Black 1 (11) 0 0 0
 Hispanic 0 3 (21) 3 (33) 0
 Other 3 (33) 0 0 0
High-risk mutation 8 (89) 10 (71) 7 (88) 3 (60)
Detected clinically 6 (67) 3 (21) 3 (33) 0
Treatment change
 No change 0 8 (57)a 5 (56)a 3 (60)a
 Desmopressin to factor 0 2 (14) 0 2 (40)
 Bypassing agent only 3 (33) 3 (21) 3 (33) 0
 ITI only 2 (22) 0 0 0
 Bypassing agent and ITI 4 (44) 1 (7) 1 (11) 0
aSignificantly different from high-titer patients at P <0.05.
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TABLE III
Characteristics of New Inhibitors Detected, Including High Titer, Low Titer, and Factor VIII (FVIII)-Specific 
Low Titer (Positive in Chromogenic Bethesda Assay and/or Fluorescence Immunoassay)
High Low FVIII-Specific Low
Inhibitor confirmation, n (%)
 FVIII-specific 8/8 (100) 9/14 (64) –
 Repeat specimen positive 7/7 (100) 7/9 (78) 7/7 (100)
Peak titer, median (range)
 Nijmegen-Bethesda assay 18.7 (2.6–688) 0.9 (0.5–1.8) 1.4 (0.5–1.8)
 Chromogenic Bethesda assay 14.8 (2.9–512) 0.8 (0–3.3) 0.9 (0.5–3.3)
 Fluorescence Immunoassay 2.89 (0.54–7.89) 0.50 (0.03–6.17) 2.71 (0.50–6.17)
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TABLE IV
Comparison of the Results of the Current Study and a Previous Large U.S. Prospective Study Conducted by 
the NHLBI [2], n (%)
NHLBI study Current study
Study Period 1975–1979 2006–2012
Number of Patients Enrolled 1306 824
Number of New Inhibitors 31 (2.4%) 23 (2.8%)
Severity
 Severe 21 (68) 15 (65)
 Moderate or mild 10 (32) 8 (35)
Age
 Median 16 5a
 Range 2–62 1–61
Exposure days
 0–20 3 (10) 10 (43)a
 21–100 14 (45) 6 (26)
 101–150 4 (13) 1 (4)
 >150 10 (32) 6 (26)
Clinical indicationb 11 (35) 9 (39)
Repeat specimen positivec 24/31 (77) 14/16 (88)
aSignificantly different at P <0.05.
b
Detected when tested due to clinical suspicion of an inhibitor rather than at study screening.
cOf those repeated.
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